JNJ Presents IMAAVY Data
Johnson & Johnson presents new IMAAVY data at European Academy of Neurology Congress, showing sustained disease control in generalized myasthenia gravis
JNJ - Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis